COVID-19 Project Team: Difference between revisions

Jump to navigation Jump to search
Ifrah Fatima (talk | contribs)
Ifrah Fatima (talk | contribs)
Line 31: Line 31:
* [[User:Agnesrinky|Rinky Agnes Botleroo, M.B.B.S.]]
* [[User:Agnesrinky|Rinky Agnes Botleroo, M.B.B.S.]]
* [[user:Nuha|Nuha AL-Howthi, MD]]
* [[user:Nuha|Nuha AL-Howthi, MD]]
* [[User:Ifrah Fatima|Ifrah Fatima, M.B.B.S]]


'''Frequently Asked Outpatient Questions Team Members'''
'''Frequently Asked Outpatient Questions Team Members'''
Line 39: Line 40:


'''Hematologic disorders of COVID-19 Team Members'''
'''Hematologic disorders of COVID-19 Team Members'''
*{{IF}}
* [[User:Ifrah Fatima|Ifrah Fatima, M.B.B.S]]
 
'''Nephrologic Disorders of COVID-19 Team Members'''
'''Nephrologic Disorders of COVID-19 Team Members'''



Revision as of 17:26, 11 June 2020

COVID-19 Project
Introduction
Team
Meetings' Summary
Topics
Ongoing Clinical Trials

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sahar Memar Montazerin, M.D.[2]

Meet The Team

Associate Editor(s)-in-Chief:

Cardiovascular Disorders of COVID-19 Team Members

Dermatologic Disorders of COVID-19 Team Members

Frequently Asked Inpatient Questions Team Members

Frequently Asked Outpatient Questions Team Members

Hematologic disorders of COVID-19 Team Members

Nephrologic Disorders of COVID-19 Team Members

Neurologic Disorders and COVID-19 Team Members

Ongoing Clinical Trials of COVID-19 Team Members


Pulmonary Disorders and COVID-19 Team Members

  • Rana Aljebzi
  • Ayesha Farheen Javid


Radiologic Manifestations of COVID-19 Team Members


Other Team Members